» Articles » PMID: 21054577

Effect of Insulin-like Growth Factor-1 Deficiency or Administration on the Occurrence of Acne

Overview
Date 2010 Nov 9
PMID 21054577
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of growth hormone, insulin, and insulin-like growth factor-1 (IGF-1) in the development of acne is incompletely understood.

Objective: To study the effect of the absence of IGF-1 and its pharmacologic replacement on the occurrence of acne vulgaris.

Patients And Methods: Laron syndrome (LS) is characterized by congenital IGF-1 deficiency. The study group consisted of 21 patients with classical LS, who underwent puberty: 13 (8 male, 5 female) untreated and under regular follow-up until age 20?48 years; and 8 (2 male, 6 female) treated with IGF-1 (70-200 μg/kg/day), including 6 adults (2 male, treated at age 14.5-29 years and 4 female, treated at age 30-37 years) and 2 adolescents (2 female, treated at age 3.5-16 years). The medical files were reviewed for occurrence of acne and the corresponding sex hormone levels, and the findings were compared between the treated and untreated patients.

Results: Puberty was delayed in all untreated patients. Only one patient had slight acne at age 22 years, when he reached full puberty. Among the 2 IGF-1 treated male patients, none acquired acne. Among the 6 treated female patients, 3 had signs of hyperandrogenism (oligo-amenorrhea) and acne during IGF-1 over-dosage. On reduction of the IGF-1 dose (to 50 μg/kg/day) or cessation of treatment, the acne disappeared in all 3 patients.

Conclusion: This study demonstrates for the first time that serum IGF-1 deficiency prevents the occurrence of acne. The findings suggest that an interaction between IGF-1 and androgens is necessary for the development of acne.

Citing Articles

Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.

Kim H, Kim Y Int J Mol Sci. 2024; 25(10).

PMID: 38791344 PMC: 11121268. DOI: 10.3390/ijms25105302.


Acne-induced pathological scars: pathophysiology and current treatments.

Xu W, Sinaki D, Tang Y, Chen Y, Zhang Y, Zhang Z Burns Trauma. 2024; 12:tkad060.

PMID: 38585341 PMC: 10998535. DOI: 10.1093/burnst/tkad060.


Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment.

Melnik B Cells. 2023; 12(22).

PMID: 37998335 PMC: 10670572. DOI: 10.3390/cells12222600.


Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesity.

Hasse L, Jamiolkowski D, Reschke F, Kapitzke K, Weiskorn J, Kordonouri O Endocr Connect. 2023; 12(9).

PMID: 37410088 PMC: 10448574. DOI: 10.1530/EC-23-0235.


Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.

Su Z, Zhang Y, Cao J, Sun Y, Cai Y, Zhang B J Nanobiotechnology. 2023; 21(1):55.

PMID: 36803994 PMC: 9938603. DOI: 10.1186/s12951-023-01812-7.